1. Anttila, A., Pukkala, E., Söderman, B., et al. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963–1995: recent increase in cervical cancer incidence. Int J Cancer, 1999, 83, p. 59–65.
2. Arbyn, M., Ronco, G., Anttila, A., et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine, 2012, 30 Suppl 5, p. F88–F99.
3. Arbyn, M., de Sanjosé, S., Saraiya, M., et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer, 2012, 131, p. 1969–1982.
4. Arbyn, M., Raifu, AO., Weiderpass, E., et al. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer, 2009, 45, p. 2640–2648.
5. Bruni, L., Barrionuevo-Rosas, L., Albero, G., et al. Human papillomavirus and related diseases in the world. Summary report 2015-04-08. Information Centre on HPV and Cancer (HPV Information Centre) 2015.
6. Bulk, S., Visser, O., Rozendaal, L., et al. Cervical cancer in the Netherlands 1989–1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer, 2005, 113, p. 1005–1009.
7. Castellsagué, X., Díaz, M., de Sanjosé, S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J National Cancer Institute, 2006, 98, p. 303–315.
8. Cogliano, V., Baan, R., Straif, K., et al. Carcinogenicity of human papillomaviruses. Lancet Oncol, 2005, 6, p. 204.
9. Cuzick, J., Clavel, C., Petry, K., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer, 2006, 119, p. 1095–1101.
10. Dalstein, V., Merlin, S., Bali, C., et al. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus. J Virol Methods, 2009, 156, p. 77–83.
11. Duskova, J., Bekova, A., Dvorak, V., et al. Results of the Czech National Cervical Cancer screening programme. Klin Onkol, 2014, 27, Suppl. 2, p. 79–86.
12. Geraets, DT., Cuschieri, K., de Koning, MN., et al. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol, 2014, 52, p. 3996–4002.
13. Gok, M., Heideman, DA., van Kemenade, FJ., et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ, 2010, 340, p. c1040.
14. Gok, M., van Kemenade, FJ., Heideman, DA., et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer, 2012, 130, p. 1128–1135.
15. http: and globocan.iarc.fr/. 18-5-0015. (GENERIC). Ref Type: Report.
16. Majek, O., Dvorak, V., Dusek, L., et al. Cervarix.cz – Program cervikálního screeningu v České republice. Int J Lab Hematol, 6-5-2015. (GENERIC). Ref Type: Online Source.
17. Munoz, N., Bosch, FX., Castellsagué, X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer, 2004, 111, p. 278–285.
18. Petignat, P., Faltin, DL., Bruchim, I., et al. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol, 2007, 105, p. 530–535.
19. Peto, J., Gilham, C., Fletcher, O., Matthews, FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet, 2004, 364, p. 249–256.
20. Preisler, S., Rebolj, M., Untermann, A., et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PloS One, 2013, 8, p. e59765.
21. Rijkaart, DC., Berkhof, J., van Kemenade, FJ., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer, 2012, 130, p. 602–610.
22. Rijkaart, DC., Berkhof, J., Rozendaal, L., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol, 2012, 13, p. 78–88.
23. Ronco, G., Giorgi-Rossi, P., Carozzi, F., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol, 2010, 11, p. 249–257.
24. Rossi, PG., Marsili, LM., Camilloni, L., et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Brit J Cancer, 2011, 104, p. 248–254.
25. Snijders, PJ., Verhoef, VM., Arbyn, M., et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer, 2013, 132, p. 2223–2236.
26. Tachezy, R., Smahelova, J., Kaspirkova, J., Salakova, M. Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women. PloS One, 2013, 8, p. e79156.
27. van Baars, R., Bosgraaf, RP., ter Harmsel, BW., et al. Dry storage and transport of a cervicovaginal self-sample by use of the evalyn brush, providing reliable human papillomavirus detection combined with comfort for women. J Clin Microbiol, 2012, 50, p. 3937–3943.
28. Walboomers, JM., Jacobs, MV., Manos, MM., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189, p. 12–19.